Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N7: High-Dose Chemo + 3F8 in Neuroblastoma
NCT00002634Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 1995
- Primary completion
- Sep 2004
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anti-GD2 monoclonal antibody 3F8 in neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Complete Remission Rate at 2 years, Progression-Free Survival at 2 years and 1 more. Started Feb 1995; status: completed.
02
Drugs
anti-GD2 monoclonal antibody 3F8
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT00002634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002634.